Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum

BackgroundThe complement system is a key component of innate immunity implicated in the neutralization and clearance of invading pathogens. Dextran coated superparamagnetic iron oxide (SPIO) nanoparticle is a promising magnetic resonance imaging (MRI) contrast agent. However, dextran SPIO has been associated with significant number of complement-related side effects in patients and some agents have been discontinued from clinical use (e.g., Feridex™). In order to improve the safety of these materials, the mechanisms of complement activation by dextran-coated SPIO and the differences between mice and humans need to be fully understood.Methods20 kDa dextran coated SPIO nanoworms (SPIO NW) were synthesized using Molday precipitation procedure. In vitro measurements of C3 deposition on SPIO NW using sera genetically deficient for various components of the classical pathway (CP), lectin pathway (LP) or alternative pathway (AP) components were used to study mechanisms of mouse complement activation. In vitro measurements of fluid phase markers of complement activation C4d and Bb and the terminal pathway marker SC5b-C9 in normal and genetically deficient sera were used to study the mechanisms of human complement activation. Mouse data were analyzed by non-paired t-test, human data were analyzed by ANOVA followed by multiple comparisons with Student-Newman-Keuls test.ResultsIn mouse sera, SPIO NW triggered the complement activation via the LP, whereas the AP contributes via the amplification loop. No involvement of the CP was observed. In human sera the LP together with the direct enhancement of the AP turnover was responsible for the complement activation. In two samples out of six healthy donors there was also a binding of anti-dextran antibodies and C1q, suggesting activation via the CP, but that did not affect the total level of C3 deposition on the particles.ConclusionsThere were important differences and similarities in the complement activation by SPIO NW in mouse versus human sera. Understanding the mechanisms of immune recognition of nanoparticles in mouse and human systems has important preclinical and clinical implications and could help design more efficient and safe nano-formulations.

[1]  S Askari,et al.  A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. , 1996, Immunity.

[2]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[3]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[4]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[5]  P. Berche,et al.  Activation of the human complement alternative pathway by Listeria monocytogenes: evidence for direct binding and proteolysis of the C3 component on bacteria , 1993, Infection and immunity.

[6]  T. Fujita,et al.  The lectin‐complement pathway – its role in innate immunity and evolution , 2004, Immunological reviews.

[7]  S. Moein Moghimi,et al.  Nanomedicine and the complement paradigm. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[8]  Michael R Hamblin,et al.  Deficiency of Mannose-Binding Lectin Greatly Increases Susceptibility to Postburn Infection with Pseudomonas aeruginosa1 , 2006, The Journal of Immunology.

[9]  P. S. Appukuttan,et al.  Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. , 2003, Molecular immunology.

[10]  V. M. Holers,et al.  Role of C3a Receptors, C5a Receptors, and Complement Protein C6 Deficiency in Collagen Antibody-Induced Arthritis in Mice , 2012, The Journal of Immunology.

[11]  U. Holmskov,et al.  Collectin 11 (CL-11, CL-K1) Is a MASP-1/3–Associated Plasma Collectin with Microbial-Binding Activity , 2010, The Journal of Immunology.

[12]  C. Vauthier,et al.  Complement Activation by Core–Shell Poly(isobutylcyanoacrylate)–Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide , 2006, Pharmaceutical Research.

[13]  A. Weintraub,et al.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. , 2006, The Journal of clinical investigation.

[14]  R. Müller,et al.  Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. , 2005, Biomaterials.

[15]  M. Munakata,et al.  Human M-Ficolin Is a Secretory Protein That Activates the Lectin Complement Pathway1 , 2005, The Journal of Immunology.

[16]  T. Fujita,et al.  Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. , 2011, Molecular immunology.

[17]  Jeff W M Bulte,et al.  Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.

[18]  T. Pellegrino,et al.  From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. , 2010, Pharmacological research.

[19]  S. Bhatia,et al.  Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging , 2008, Advanced materials.

[20]  S. Moghimi,et al.  Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[21]  P. Lachmann.  Preparing serum for functional complement assays. , 2010, Journal of immunological methods.

[22]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[23]  M. Botto.  C1q Knock-Out Mice for the Study of Complement Deficiency in Autoimmune Disease , 1999, Experimental and Clinical Immunogenetics.

[24]  H. Colten,et al.  Abrogation of the alternative complement pathway by targeted deletion of murine factor B. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Tsigelny,et al.  Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. , 2012, Bioconjugate chemistry.

[26]  S. Thiel,et al.  Improvements on the purification of mannan-binding lectin and demonstration of its Ca(2+)-independent association with a C1s-like serine protease. , 1996, The Biochemical journal.

[27]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[28]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[29]  I. Tsigelny,et al.  Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. , 2013, ACS nano.

[30]  T. Fujita,et al.  The Role of Mannose-Binding Lectin-Associated Serine Protease-3 in Activation of the Alternative Complement Pathway , 2011, The Journal of Immunology.

[31]  S Moein Moghimi,et al.  Complement: alive and kicking nanomedicines. , 2009, Journal of biomedical nanotechnology.

[32]  P. Jacobs,et al.  Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[33]  R. Molday,et al.  Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. , 1982, Journal of immunological methods.

[34]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[35]  A. Weintraub,et al.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2 , 2006 .

[36]  Shigeto Miura,et al.  Mannose-Binding Lectin (MBL)-Associated Serine Protease (MASP)-1 Contributes to Activation of the Lectin Complement Pathway1 , 2008, The Journal of Immunology.

[37]  Hongjie Dai,et al.  Single-walled carbon nanotube surface control of complement recognition and activation. , 2013, ACS nano.

[38]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  C. Hack,et al.  Functional characterization of the lectin pathway of complement in human serum. , 2003, Molecular immunology.

[40]  P. Andrew,et al.  The Lectin Pathway of Complement Activation Is a Critical Component of the Innate Immune Response to Pneumococcal Infection , 2012, PLoS pathogens.

[41]  E. Buescher,et al.  Cleavage of Complement C3b to iC3b on the Surface of Staphylococcus aureus Is Mediated by Serum Complement Factor I , 2004, Infection and Immunity.

[42]  L. Diehl,et al.  CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens , 2006, Cell.

[43]  Dipak K. Sarker,et al.  Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.

[44]  P Couvreur,et al.  Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. , 1997, Life sciences.

[45]  Samuel A Wickline,et al.  Variable Antibody-dependent Activation of Complement by Functionalized Phospholipid Nanoparticle Surfaces* , 2010, The Journal of Biological Chemistry.

[46]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[47]  T. Lint,et al.  Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. , 1998, Journal of immunology.

[48]  Robert Langer,et al.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.

[49]  R. Weissleder,et al.  Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.

[50]  S. Esener,et al.  Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles. , 2012, Molecular pharmaceutics.

[51]  Wuding Zhou,et al.  The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. , 2009, Inflammation & allergy drug targets.

[52]  T. Fujita,et al.  Essential Role of Complement Mannose-Binding Lectin-Associated Serine Proteases-1/3 in the Murine Collagen Antibody-Induced Model of Inflammatory Arthritis , 2010, The Journal of Immunology.

[53]  C. W. Jung.  Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[54]  Ji-Ho Park,et al.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.

[55]  M. Turner,et al.  Mannose-binding lectin: the pluripotent molecule of the innate immune system. , 1996, Immunology today.